Responses
Immune cell therapies and immune cell engineering
Original research
Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China
Compose a Response to This Article
Other responses
No responses have been published for this article.
